Bioequivalence assessment of two Ticagrelor formulations under fasting condition in healthy Pakistani subjects

OBJECTIVE: To investigate the Bioequivalence of Anplag® 90mg (Ticagrelor) tablet and Brilinta® 90 mg (Ticagrelor) tablet under fasting conditions in healthy Pakistani subjects. METHOD: This was an open-label, cross-over, randomized, single-dose, two-period, single-center Bioequivalence Study conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashmi, Naghma, Jawaid, Masood, Shah, Muhammad Raza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626117/
https://www.ncbi.nlm.nih.gov/pubmed/37936786
http://dx.doi.org/10.12669/pjms.39.6.8203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626117/
https://www.ncbi.nlm.nih.gov/pubmed/37936786
http://dx.doi.org/10.12669/pjms.39.6.8203

Ejemplares similares